Bevacizumab and CHOP (A-CHOP) [cyclophosphamide, doxorubicin, vincristine, prednisone] in combination for patients with peripheral T-cell or natural killer cell neoplasms
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 07 May 2014 Biomarkers information updated
- 12 Mar 2009 Status changed from recruiting to suspended, according to ClinicalTrials.gov.
- 20 Feb 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center).